Pfizer’s Somavert to be funded by NHS Wales

The All Wales Medicines Strategy Group has recommended Somavert (pegvisomant) as an option for routine use on the NHS in Wales for the treatment of adults with acromegaly who have had an inadequate response to surgery and/or radiotherapy, and in whom an appropriate medical treatment with somatostatin analogues was not effective enough or not tolerated.
Pharma Times